Passage Bio (PASG) Expected to Post Quarterly Earnings on Monday

Passage Bio (NASDAQ:PASG) is expected to be issuing its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect the company to announce earnings of ($2.27) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

Passage Bio (NASDAQ:PASG) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($2.36) EPS for the quarter, topping the consensus estimate of ($2.76) by $0.40. On average, analysts expect Passage Bio to post $-9 EPS for the current fiscal year and $-9 EPS for the next fiscal year.

Passage Bio Trading Down 0.4%

Shares of PASG opened at $4.47 on Friday. Passage Bio has a twelve month low of $3.29 and a twelve month high of $20.00. The company has a market cap of $14.35 million, a P/E ratio of -0.38 and a beta of 1.42. The company’s fifty day simple moving average is $5.14 and its 200-day simple moving average is $7.39.

Wall Street Analyst Weigh In

PASG has been the subject of a number of recent analyst reports. Wedbush reaffirmed a “neutral” rating and set a $8.00 price target (down from $32.00) on shares of Passage Bio in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Passage Bio from a “sell” rating to a “hold” rating in a research report on Saturday. TD Cowen downgraded shares of Passage Bio from a “buy” rating to a “hold” rating in a research note on Tuesday, April 21st. Chardan Capital set a $7.00 target price on Passage Bio and gave the company a “neutral” rating in a research report on Tuesday, April 21st. Finally, Lucid Cap Mkts lowered Passage Bio from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.25.

Insider Activity

In related news, major shareholder Lynx1 Capital Management Lp bought 50,055 shares of the stock in a transaction dated Thursday, June 25th. The stock was purchased at an average cost of $4.12 per share, with a total value of $206,226.60. Following the completion of the purchase, the insider owned 673,759 shares of the company’s stock, valued at $2,775,887.08. This trade represents a 8.03% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 4.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Quadrature Capital Ltd purchased a new stake in Passage Bio in the 4th quarter valued at about $148,000. Squarepoint Ops LLC purchased a new position in shares of Passage Bio during the third quarter worth approximately $188,000. Geode Capital Management LLC increased its position in shares of Passage Bio by 15.1% during the fourth quarter. Geode Capital Management LLC now owns 31,397 shares of the company’s stock worth $371,000 after acquiring an additional 4,114 shares during the period. Yiheng Capital Management L.P. bought a new stake in shares of Passage Bio during the fourth quarter valued at approximately $405,000. Finally, Renaissance Technologies LLC raised its stake in shares of Passage Bio by 8.2% during the fourth quarter. Renaissance Technologies LLC now owns 109,089 shares of the company’s stock valued at $1,287,000 after acquiring an additional 8,300 shares in the last quarter. Hedge funds and other institutional investors own 53.48% of the company’s stock.

Passage Bio Company Profile

Passage Bio is a clinical-stage biotechnology company focused on the development of gene therapies to treat rare, monogenic central nervous system and neuromuscular disorders. The company applies its in-house gene therapy platform to design and engineer adeno-associated virus (AAV)–based vectors that restore or replace defective genes, aiming to deliver durable treatments with a single administration.

The company’s lead programs include PBGM01, an AAV9-based therapy for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), which is conducting a first-in-human study to assess safety and potential therapeutic benefit.